| 张勇华,陈艳红,陈 耽,李 希,郭在雄,苏 晞.血清LncRNA MALAT1、miR-150-5p与心房颤动患者射频消融术后复发的关系研究[J].,2024,(18):3595-3600 |
| 血清LncRNA MALAT1、miR-150-5p与心房颤动患者射频消融术后复发的关系研究 |
| Study of the Relationship between Serum LncRNA MALAT1, miR-150-5p and Recurrence after Radiofrequency Catheter Ablation in Patients with Atrial Fibrillation |
| 投稿时间：2024-01-26 修订日期：2024-02-21 |
| DOI：10.13241/j.cnki.pmb.2024.18.037 |
| 中文关键词: 心房颤动 LncRNA MALAT1 miR-150-5p 射频消融术 复发 |
| 英文关键词: Atrial fibrillation LncRNA MALAT1 miR-150-5p Radiofrequency catheter ablation Recurrence |
| 基金项目:湖北省卫生计生科研基金全新团队资助项目（WJ2018H0043）；武汉市医学科研项目（WX20C28） |
|
| 摘要点击次数: 126 |
| 全文下载次数: 74 |
| 中文摘要: |
| 摘要 目的：探讨血清长链非编码核糖核酸肺腺癌转移相关转录本1（LncRNA MALAT1）、微小核糖核酸（miRNA）-150-5p与心房颤动患者射频消融术（RFCA）后复发的关系。方法：选取2021年1月～2022年6月在武汉亚洲心脏病医院和华中科技大学同济医学院附属梨园医院行RFCA治疗的AF患者117例作为AF组，另选取同期76名体检健康志愿者作为对照组。随访1年根据是否复发将AF患者分为复发组和未复发组。通过实时荧光定量聚合酶链式反应检测血清LncRNA MALAT1、miR-150-5p表达。采用Pearson相关性分析LncRNA MALAT1与miR-150-5p在AF血清中表达的相关性。多因素Logistic回归分析影响AF患者RFCA后复发的因素，受试者工作特征（ROC）曲线分析血清LncRNA MALAT1、miR-150-5p对AF患者RFCA后复发的预测价值。结果：与对照组比较，AF组血清LncRNA MALAT1表达升高，miR-150-5p表达降低（P＜0.05）。AF患者血清LncRNA MALAT1与miR-150-5p表达呈负相关（r=-0.737，P＜0.001）。随访1年，117例AF患者RFCA复发率为35.04%（41/117）。与未复发组比较，复发组血清LncRNA MALAT1表达升高，miR-150-5p表达降低（P＜0.05）。多因素Logistic回归分析显示病程延长、持续性AF、CHA2DS2-VASc评分增加、LncRNA MALAT1升高为AF患者RFCA后复发的独立危险因素，miR-150-5p升高为独立保护因素（P＜0.05）。血清LncRNA MALAT1联合miR-150-5p预测的曲线下面积为0.893，大于血清LncRNA MALAT1、miR-150-5p单独预测的0.785、0.786。结论：AF患者血清LncRNA MALAT1高表达、miR-150-5p低表达，与RFCA后复发密切相关。血清LncRNA MALAT1联合miR-150-5p对AF患者RFCA后复发具有较高的预测价值。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the relationship between serum long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 (LncRNA MALAT1), microRNA (miRNA)-150-5p and recurrence after radiofrequency catheter ablation (RFCA) in patients with atrial fibrillation. Methods: 117 AF patients who underwent RFCA in Wuhan Asia Heart Hospital and Liyuan Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology from January 2021 to June 2022 were selected as AF group, and 76 healthy volunteers were selected as control group. AF patients were divided into recurrence group and non-recurrence group according to whether they relapsed after 1 year of follow-up. The expression of serum LncRNA MALAT1 and miR-150-5p was detected by real-time fluorescence quantitative polymerase chain reaction. The correlation between LncRNA MALAT1 and miR-150-5p expression in AF serum were analyzed by Pearson correlation analysis. The factors affecting the recurrence of AF patients after RFCA were analyzed by multivariate Logistic regression analysis. The predictive value of serum LncRNA MALAT1 and miR-150-5p on the recurrence of AF patients after RFCA were analyzed by receiver operating characteristic (ROC) curve. Results: Compared with control group, the expression of serum LncRNA MALAT1 in AF group was increased, and the expression of miR-150-5p was decreased (P<0.05). Serum LncRNA MALAT1 was negatively correlated with miR-150-5p expression in AF patients (r=-0.737, P<0.001). After 1 year of follow-up, the recurrence rate of RFCA in 117 AF patients was 35.04% (41/117). Compared with non-recurrence group, the expression of serum LncRNA MALAT1 in recurrence group was increased, and the expression of miR-150-5p was decreased (P<0.05). Multivariate Logistic regression analysis showed that prolonged course of disease, persistent AF, increased CHA2DS2-VASc score, and increased LncRNA MALAT1 were independent risk factors for recurrence after RFCA in AF patients, and increased miR-150-5p was an independent protective factor (P<0.05). The area under the curve predicted by serum LncRNA MALAT1 combined with miR-150-5p was 0.893, which was greater than 0.785 and 0.786 predicted by serum LncRNA MALAT1 and miR-150-5p alone. Conclusion: High expression of serum LncRNA MALAT1 and low expression of miR-150-5p in AF patients, which are closely relate to recurrence after RFCA. Serum LncRNA MALAT1 combine with miR-150-5p has a high predictive value for recurrence in AF patients after RFCA. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
